Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Keita Kudo
Observed names:
KEITA KUDO,
Keita KUDO
Institution:
Osaka Minami Medical Center
Observed institutions:
Kindai University Hospital,
Osaka Minami Medical Center,
The Cancer Institute Hospital,
Toranomon Hospital,
Japanese Foundation For Cancer Research,
Kindai University
show all 6
ORCID:
0009-0009-8390-2600
Observed ORCID:
0009-0009-8390-2600
OpenAlex ID:
A5103694083
Association of Immune-Related Adverse Events With Nivolumab Efficacy in Non–Small-Cell Lung Cancer
2017
·
Koji Haratani
, Hidetoshi Hayashi
, et al.
·
JAMA Oncology
·
1,029
Peripheral Blood Biomarkers Associated with Clinical Outcome in Non–Small Cell Lung Cancer Patients Treated with Nivolumab
2017
·
Junko Tanizaki
, Koji Haratani
, et al.
·
Journal of Thoracic Oncology
·
240
B7-H3 Negatively Modulates CTL-Mediated Cancer Immunity
2018
·
Kimio Yonesaka
, Koji Haratani
, et al.
·
Clinical Cancer Research
·
178
Detection of epidermal growth factor receptor T790M mutation in plasma DNA from patients refractory to epidermal growth factor receptor tyrosine kinase inhibitor
2013
·
Kazuko Sakai
, Atsushi Horiike
, et al.
·
Cancer Science
·
79
The pan-HER family tyrosine kinase inhibitor afatinib overcomes HER3 ligand heregulin-mediated resistance to EGFR inhibitors in non-small cell lung cancer
2015
·
Kimio Yonesaka
, Keita Kudo
, et al.
·
Oncotarget
·
67
PDF
Sorafenib treatment for patients with RET fusion-positive non-small cell lung cancer
2015
·
Atsushi Horiike
, Kengo Takeuchi
, et al.
·
Lung Cancer
·
57
PDF
Early onset recall pneumonitis during targeted therapy with sunitinib
2013
·
Takeshi Yuasa
, Shinichi Kitsukawa
, et al.
·
BMC Cancer
·
27
PDF
Pemetrexed and cisplatin for advanced non-squamous non-small cell lung cancer in Japanese patients: phase II study.
2013
·
Yuko Kawano
, Fumiyoshi Ohyanagi
, et al.
·
PubMed
·
26
Phase II trial of S‐1 treatment as palliative‐intent chemotherapy for previously treated advanced thymic carcinoma
2020
·
Yusuke Okuma
, Yasushi Goto
, et al.
·
Cancer Medicine
·
23
The Tumor Immune Microenvironment and Frameshift Neoantigen Load Determine Response to PD-L1 Blockade in Extensive-Stage SCLC
2022
·
Hiroaki Kanemura
, Hidetoshi Hayashi
, et al.
·
JTO Clinical and Research Reports
·
22
PDF
Clinicopathological findings of non-small-cell lung cancer with high serum progastrin-releasing peptide concentrations
2011
·
Keita Kudo
, Fumiyoshi Ohyanagi
, et al.
·
Lung Cancer
·
21
Phase II study of erlotinib for acquired resistance to gefitinib in patients with advanced non-small cell lung cancer.
2014
·
Atsushi Horiike
, Nobuyuki Yamamoto
, et al.
·
PubMed
·
20
Phase I study of the anti-MET antibody onartuzumab in patients with solid tumors and MET-positive lung cancer
2015
·
Makoto Nishio
, Atsushi Horiike
, et al.
·
Investigational New Drugs
·
16
Second-line immunosuppressant administration for steroid-refractory immune-related adverse events in patients with lung cancer
2023
·
Shinsuke Ogusu
, Yuhei Harutani
, et al.
·
Cancer Immunology Immunotherapy
·
15
PDF
Successful treatment with afatinib after gefitinib- and erlotinib-induced hepatotoxicity
2016
·
Hiroto Ueda
, Hidetoshi Hayashi
, et al.
·
Investigational New Drugs
·
15
Phase II study of docetaxel-plus-bevacizumab combination therapy in patients previously treated for advanced non-squamous non-small cell lung cancer.
2014
·
Fumiyoshi Ohyanagi
, Noriko Yanagitani
, et al.
·
PubMed
·
14
Risk and survival of patients with non-small cell lung cancer and pre-existing autoimmune disorders receiving immune checkpoint blockade therapy: Survival analysis with inverse probability weighting from a nationwide, multi-institutional, retrospective study (NEJ047)
2024
·
Tetsuhiko Asao
, Takehito Shukuya
, et al.
·
Lung Cancer
·
11
PDF
Clinical efficacy of amrubicin in patients with small cell lung cancer relapse after first‐line treatment including immune checkpoint inhibitors: A retrospective multicenter study ( TOPGAN 2021‐01)
2022
·
Shinya Uematsu
, Satoru Kitazono
, et al.
·
Thoracic Cancer
·
9
PDF
Medical Practice Guidelines for Lung Cancers including malignant pleural mesotheliomas and thymic tumors according to evidence-based medicine. 2024. Edited by the Japan Lung Cancer Society. Chapter 3 Guidelines for thymic epithelial tumors – Summary of recommendations
2025
·
Meinoshin Okumura
, Kiminori Fujimoto
, et al.
·
Respiratory Investigation
·
8
Impact of B7-H3 and DLL3 expression on the efficacy of PD-L1 blockade therapy in extensive-stage small cell lung cancer
2025
·
Takashi Kurosaki
, Hiroaki Kanemura
, et al.
·
Lung Cancer
·
7
PDF
Comparison of immune checkpoint inhibitor plus chemotherapy or ipilimumab plus nivolumab-based therapy for NSCLC patients with PD-L1 TPS (1–49 %): TOPGAN2023-01
2024
·
Hisashi Tanaka
, Tomonori Makiguchi
, et al.
·
European Journal of Cancer
·
7
PDF
Serum immune modulators during the first cycle of anti‐PD‐1 antibody therapy in non‐small cell lung cancer: Perforin as a biomarker
2020
·
Takayo Ota
, Tomoya Fukui
, et al.
·
Thoracic Cancer
·
6
PDF
Plasma homocysteine levels and hematological toxicity in NSCLC patients after the first cycle of pemetrexed under folate supplementation
2015
·
Hisashi Tanaka
, Atsushi Horiike
, et al.
·
Anti-Cancer Drugs
·
6
Randomized phase 2 study comparing irinotecan versus amrubicin as maintenance therapy after first‐line induction therapy for extensive disease small cell lung cancer ( HOT1401 / NJLCG1401 )
2021
·
Hisashi Tanaka
, Yukihiro Hasegawa
, et al.
·
Thoracic Cancer
·
5
PDF
Phase I/II Study of Cisplatin plus Nab-Paclitaxel with Concurrent Thoracic Radiotherapy for Patients with Locally Advanced Non-Small Cell Lung Cancer
2020
·
Hidetoshi Hayashi
, Masakazu Ogura
, et al.
·
The Oncologist
·
5
PDF
Show more works
View as search
Works count:
90
Citation count:
1,931
H-index:
15
I10-index:
17
Year
Topic
Type